Lincoff, A M <br/><br/>
Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.  [electronic resource] 

 -  Circulation  Dec 2000 
 - 2923-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1524-4539 
<br/><br/><label>Standard No.: </label>10.1161/01.cir.102.24.2923  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abciximab<br/>Aged<br/>Antibodies, Monoclonal--economics<br/>Drug Therapy, Combination<br/>Health Care Costs<br/>Hemorrhage--prevention & control<br/>Heparin--administration & dosage<br/>Humans<br/>Immunoglobulin Fab Fragments--economics<br/>Middle Aged<br/>Myocardial Ischemia--prevention & control<br/>Myocardial Revascularization--economics<br/>Platelet Aggregation Inhibitors--economics<br/>Platelet Glycoprotein GPIb-IX Complex--antagonists & inhibitors<br/>Platelet Membrane Glycoproteins<br/>Postoperative Complications--prevention & control<br/>Prospective Studies<br/>Treatment Outcome